Ebvia, Inc.

Ebvia is a privately held biotechnology company developing a novel, outpatient treatment for breakthrough COVID-19 infections. The drug candidate demonstrated 100% survival against SARS-CoV-2 infection (vs 20% in the control group) in a highly lethal animal model. It also significantly reduced lung and brain pathology in mice infected with the SARS-CoV-2 virus. The candidate is highly potent against the Delta variant and demonstrated strong efficacy against different strains of influenza in animal models.

As we enter the endemic phase of COVID-19, our vision is to provide our communities with a simple to use, safe and effective treatment to address both COVID-19 and influenza.